1C
VERV

1623 Capital’s Verve Therapeutics VERV Stock Holding History

1623 Capital’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-26,999
Closed -$413K – 49
2022
Q2 		$413K Buy
26,999
+8,158
+43% +$126K 0.26% 35
2022
Q1 		$430K Sell
18,841
-966
-5% -$27.6K 0.22% 41
2021
Q4 		$730K Buy
+19,807
New +$832K 0.27% 44

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

1623 Capital's VERV Position: Q3 2022 in Review

1623 Capital sold out of Verve Therapeutics (VERV) in Q3 2022, closing a stake of 26,999 shares — an estimated $413K sold.

1623 Capital first reported a position in VERV in Q4 2021 and held it in 3 quarters. The position peaked at $730K in Q4 2021. 125 funds tracked by Wall St. Rank hold VERV as of Q3 2022.

  • 1623 Capital reported no remaining Verve Therapeutics position as of Q3 2022 after selling out during the quarter.
  • 1623 Capital sold 26,999 Verve Therapeutics shares in Q3 2022, an estimated $413K.
  • 1623 Capital first reported a position in Verve Therapeutics in Q4 2021 and held it in 3 quarters.
  • 1623 Capital's Verve Therapeutics position peaked at $730K in Q4 2021.
  • 125 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2022.

Based on 1623 Capital's 13F filing for Q3 2022, filed 14 Nov 2022.